RSS  JOBS   SITE MAP 
 HOME 
PHARMA
BIO TECHNOLOGY
MEDICAL TECHNOLOGY
 RESOURCE CENTER 
 NEWSLETTER 
 DIGITAL MAGAZINE 
  Saturday, February 11, 2012 SEARCH     
 
 
BIO AUSTRALIA
BIO CHINA
BIO INDIA
BIO INDONESIA
BIO JAPAN
BIO KOREA
BIO MALAYSIA
BIO NEW ZEALAND
BIO PHILIPPINES
BIO SINGAPORE
BIO TAIWAN
BIO THAILAND
 
 
Get the latest news on life sciences in your mail box
Name
E-Mail Id
 
 
Advertisement

 
Medical Technology  Products  Story
Criticare Systems gets FDA nod for eVision 9100

Bangalore, Sep 6, 2010: Criticare Systems, the wholly-owned subsidiary of Opto Circuits (India) (OCI), India’s leading developer and manufacturer of patient monitoring systems and interventional products, today received Section 510(K) US FDA (United States Food & Drug Administration) clearance on new modular patient monitoring system - eVision 9100. The latest certification enables Criticare to market and commercially distribute eVision 9100 in most parts of the world, particularly in the US, which is one of the largest markets for patient monitors.

eVision 9100 is the first modular ‘green’ monitor that is environmentally-friendly and includes a trickle charge solar panel. This expandable, plug-and-play monitor measures physiological parameters of patients; parameters can be removed or changed without interruptions to the operating system. The monitor also has an optional expansion rack providing up to 15 modular slots for an unlimited array of patient monitoring solutions. It is also the only modular monitoring system to include Criticare’s patented Water Trap system.

eVision 9100 has a touch-screen display and an interactive user interface that allows the base configurations to be easily upgraded in the field (through remote access) or in the factory. Physiological data, system alarms and patient data analysis are made available to the care providers from the monitor.

Commenting on the latest development, Mr Vinod Ramnani, chairman and managing director, OCI said, “The US FDA 510(K) clearance will now enable us to commercialize eVision 9100 in the US and will help boost sales in other parts of the world. Multi-parameter monitors have the largest share in the patient monitoring market. A US FDA cleared modular vital signs monitor in our portfolio will help us capitalize on the market potential.”

Quoting Global Markets Direct, the company noted that the global revenue for multi-parameter patient monitors is estimated to be around US$ 2249 million.

Multi-parameter patient monitoring devices are used to monitor more than one patient parameter. eVision 9100 will monitor parameters such as Non-Invasive Blood Pressure (NIBP), Invasive Blood Pressure (IBP), Temperature, Respiratory Gases, Anaesthetic Agent Gases, Respiratory Rate, Pulse Oximetry, ECG and Arrhythmia and ST Analysis of the ECG waveforms. The monitor will be used in critical care and preoperative units and during surgery and emergency care.



© BioSpectrum Bureau
  Email this articleComment on this article   Print this article
 
Advertisement











 
   
 
Google
BioSpectrumAsia.com BioSpectrumIndia.com Web

About BioSpectrum | How to Advertise | Jobs at BioSpectrum | Jobs at CyberMedia | Contact Us | Privacy Statement



CyberMedia Network Websites


[Voice&Data]  [PCQuest]  [CIOL]  [Dataquest]  [Living Digital]  [IDC India]
[DQ Channels]  [The DQweek]  [DARE]  
[CyberMedia Events] [CyberMedia Digital]  [Cyber Astro]  [CyberMedia India]  [Global Services]  [BioSpectrum]

 
Copyrights are reserved for BioSpectrum ; Designed by : Altered Black